Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Current Assets (2017 - 2026)

Denali Therapeutics has reported Current Assets over the past 9 years, most recently at $900.7 million for Q4 2025.

  • Quarterly Current Assets rose 4.19% to $900.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $900.7 million through Dec 2025, up 4.19% year-over-year, with the annual reading at $900.7 million for FY2025, 4.19% up from the prior year.
  • Current Assets was $900.7 million for Q4 2025 at Denali Therapeutics, up from $882.6 million in the prior quarter.
  • Over five years, Current Assets peaked at $1.4 billion in Q1 2021 and troughed at $864.4 million in Q4 2024.
  • The 5-year median for Current Assets is $1.0 billion (2021), against an average of $1.1 billion.
  • The largest YoY upside for Current Assets was 139.85% in 2021 against a maximum downside of 40.01% in 2021.
  • A 5-year view of Current Assets shows it stood at $897.2 million in 2021, then soared by 52.95% to $1.4 billion in 2022, then fell by 22.46% to $1.1 billion in 2023, then dropped by 18.77% to $864.4 million in 2024, then rose by 4.19% to $900.7 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Current Assets are $900.7 million (Q4 2025), $882.6 million (Q3 2025), and $934.7 million (Q2 2025).